在IBS中FODMAP饮食的作用
Luisa Bertin1,2, Miriana Zanconato1,2, Martina Crepaldi1,2
1Department of Surgery, Oncology, Gastroenterology, University of Padua, 35121 Padua, Italy.
Nutrients
|February 10, 2024
概括
低FODMAP (可发酵的寡糖化物,分糖化物,单糖化物和多醇) 的饮食有助于控制易怒肠综合征 (IBS) 的症状. 本综述探讨了其机制,IBS亚型的有效性以及患者面临的实际挑战.
科学领域:
- 胃肠病学和营养科学 胃肠病学和营养科学
- 刺激性肠综合征 (IBS) 病理生理学
- 饮食干预 饮食干预
背景情况:
- 低FODMAP饮食是一种被公认的刺激性肠综合征 (IBS) 治疗策略.
- 低FODMAP饮食的有效性背后的精确机制仍然不完全理解.
- 现有的证据主要集中在饮食限制阶段的症状缓解上.
研究的目的:
- 审查IBS中低FODMAP饮食的潜在病理生理机制.
- 提供关于低FODMAP饮食在不同IBS亚型中的有效性证据的概述.
- 讨论与实施低FODMAP饮食相关的实际挑战和局限性.
主要方法:
- 关于低FODMAP饮食机制和IBS疗效的现有研究的文献综述.
- 分析病理生理因素,包括内脏过敏,肠道透性,微生物群和SCFA生产.
- 检查各种IBS子类型的证据,并考虑实际实施.
主要成果:
- 低FODMAP饮食影响了气体和水以外的多种IBS机制,包括内脏过敏,肠道透性,微生物群和SCFA生产.
- 证据证实,这种饮食有效缓解IBS症状,如胀气和疼痛,特别是在限制阶段.
- 存在重大挑战,包括需要专业指导,个体反应的变化,潜在的营养不足和微生物群的改变.
结论:
- 低FODMAP饮食对IBS症状管理是有效的,通过多种机制起作用.
- 一个全面的理解需要承认它的好处和实际限制和潜在风险.
- 需要进一步的研究,特别是对所有IBS亚型的长期影响和疗效.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Irritable Bowel Syndrome I: Introduction
275
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
275
Irritable Bowel Syndrome III: Medical and Nursing Management
208
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
208
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
161
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
161


